AJP - Endo Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 289: E272-E277, 2005. First published February 22, 2005; doi:10.1152/ajpendo.00039.2005
0193-1849/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
289/2/E272    most recent
00039.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Derave, W.
Right arrow Articles by Hespel, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Derave, W.
Right arrow Articles by Hespel, P.

No effects of lifelong creatine supplementation on sarcopenia in senescence-accelerated mice (SAMP8)

Wim Derave, Bert O. Eijnde, Monique Ramaekers, and Peter Hespel

Laboratory of Exercise Physiology and Biomechanics, Faculty of Kinesiology and Rehabilitation Sciences, K.U. Leuven, Leuven, Belgium

Submitted 28 January 2005 ; accepted in final form 16 February 2005

Oral creatine supplementation can acutely ameliorate skeletal muscle function in older humans, but its value in the prevention of sarcopenia remains unknown. We evaluated the effects of lifelong creatine supplementation on muscle mass and morphology, contractility, and metabolic properties in a mouse model of muscle senescence. Male senescence-accelerated mice (SAMP8) were fed control or creatine-supplemented (2% of food intake) diet from the age of 10 to 60 wk. Soleus and extensor digitorum longus muscles were tested for in vitro contractile properties, creatine content, and morphology at weeks 25 and 60. Both muscle types showed reduced phosphocreatine content at week 60 that could not be prevented by creatine. Accordingly, age-associated decline in muscle mass and contractility was not influenced by treatment. Aged soleus muscles had fewer and smaller fast-twitch glycolytic fibers irrespective of treatment received. It is concluded that lifelong creatine supplementation is no effective strategy to prevent sarcopenia in senescence-accelerated mice.

muscle fiber; atrophy; contractile properties


Address for reprint requests and other correspondence: W. Derave, Exercise Physiology and Biomechanics Laboratory, Faculty of Kinesiology and Rehabilitation Sciences, Tervuursevest 101, B-3001 Leuven, Belgium (e-mail: wim.derave{at}faber.kuleuven.be)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.